Day: September 23, 2023

– The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit – Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency (GHD). Results were shared today in Poster LB-17 at ESPE 2023, the annual meeting of the European Society for Paediatric Endocrinology being held in The Hague, September 21-23. The enliGHten trial enrolled 298 participants (mean...

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) — Reflex Advanced Materials Corp. (CSE:RFLX) (FSE:HF2) (“Reflex” or the “Company”) announces an amendment to the terms of its non-brokered private placement financing (the “Private Placement”) previously announced on August 21, 2023. The Private Placement is now comprised of up to 5,000,000 units of the Company (“Units”) at an updated price of $0.20 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit continues to consist of one (1) common share in the capital of the Company (“Share”) and one-half (1/2) of one (1) Share purchase warrant (“Warrant”), whereby each whole Warrant will entitle the holder thereof to purchase an additional Share at an exercise...